PMID- 34371506
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20230902
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Print)
IS  - 0959-4973 (Linking)
VI  - 33
IP  - 1
DP  - 2022 Jan 1
TI  - The efficacy and safety of palbociclib combined with endocrine therapy in 
      patients with hormone receptor-positive HER2-negative advanced breast cancer: a 
      multi-center retrospective analysis.
PG  - e635-e643
LID - 10.1097/CAD.0000000000001210 [doi]
AB  - To explore the efficacy and safety of palbociclib combined with endocrine therapy 
      (ET) in advanced breast cancer (ABC). We conducted a retrospective study 
      involving patients with hormone receptor-positive (HR+) and human epidermal 
      growth factor receptor 2-negative (HER2-) ABC who received palbociclib combined 
      with ET in the first- to third-line at three centers in China between January 
      2018 and October 2020. A total of 151 patients were included in this study. The 
      median age of the patients at palbociclib initiation was 56 years (range 30-86 
      years) with a median follow-up of 10.9 months (range 2.0-41.2 months). Among 
      these patients, 88 patients received palbociclib combined with ET as first-line 
      therapy, and achieved a median progression-free survival (mPFS) of 19.8 months 
      and an objective response rate (ORR) of 40.9%, meanwhile, in the first-line 
      setting, 62 patients received palbociclib at an initial dose of 125 mg, achieving 
      a mPFS of 20.9 months and an ORR of 46.8%. There were 39 and 24 patients who 
      received palbociclib combined with ET as second- and third-line therapy, the mPFS 
      were 10.0 months and 6.1 months, respectively. The most common and serious 
      adverse events (AEs) were leukopenia and neutropenia. A total of 64 patients 
      (42.4%) underwent palbociclib dose reduction due to AEs. Palbociclib combined 
      with ET is an effective therapeutic regimen for HR+/HER2- ABC, particularly in 
      the first-line setting with palbociclib initial dose of 125 mg, and AEs were 
      manageable.
CI  - Copyright (c) 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Zhang, Linhui
AU  - Zhang L
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Breast Oncology, Peking University Cancer 
      Hospital & Institute, Hai-Dian District.
FAU - Song, Guohong
AU  - Song G
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Breast Oncology, Peking University Cancer 
      Hospital & Institute, Hai-Dian District.
FAU - Shao, Bin
AU  - Shao B
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Breast Oncology, Peking University Cancer 
      Hospital & Institute, Hai-Dian District.
FAU - Xu, Ling
AU  - Xu L
AD  - Department of Breast Disease Center, Peking University First Hospital, Xi Cheng 
      District.
FAU - Xiao, Yu
AU  - Xiao Y
AD  - Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third 
      Hospital, Hai-Dian District, Beijing, China.
FAU - Wang, Mopei
AU  - Wang M
AD  - Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third 
      Hospital, Hai-Dian District, Beijing, China.
FAU - Sumou, Ingrid Karmane
AU  - Sumou IK
AD  - Department of Oncology, Centro Hospitalar Conde de Sao Januario (CHCSJ), Macao 
      Special Administrative Region of China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Breast Oncology, Peking University Cancer 
      Hospital & Institute, Hai-Dian District.
FAU - Liang, Xu
AU  - Liang X
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Breast Oncology, Peking University Cancer 
      Hospital & Institute, Hai-Dian District.
FAU - Jiang, Hanfang
AU  - Jiang H
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Breast Oncology, Peking University Cancer 
      Hospital & Institute, Hai-Dian District.
FAU - Li, Huiping
AU  - Li H
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Breast Oncology, Peking University Cancer 
      Hospital & Institute, Hai-Dian District.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Piperazines)
RN  - 0 (Pyridines)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - G9ZF61LE7G (palbociclib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Breast Neoplasms/*drug therapy
MH  - China
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Piperazines/administration & dosage/adverse effects/*therapeutic use
MH  - Progression-Free Survival
MH  - Pyridines/administration & dosage/adverse effects/*therapeutic use
MH  - Receptor, ErbB-2/biosynthesis
PMC - PMC8670355
COIS- There are no conflicts of interest.
EDAT- 2021/08/10 06:00
MHDA- 2022/03/09 06:00
PMCR- 2021/12/14
CRDT- 2021/08/09 20:29
PHST- 2021/08/10 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2021/08/09 20:29 [entrez]
PHST- 2021/12/14 00:00 [pmc-release]
AID - 00001813-202201000-00082 [pii]
AID - 10.1097/CAD.0000000000001210 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2022 Jan 1;33(1):e635-e643. doi: 10.1097/CAD.0000000000001210.